This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Neurocrine Announces Start Of Second Phase IIb Study Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia

SAN DIEGO, Dec. 18, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase IIb clinical trial (Kinect 2 Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this six-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled, dose titration trial of 90 subjects with moderate to severe tardive dyskinesia and underlying mood disorders, gastrointestinal disorders, and schizophrenia or schizoaffective disorder. Topline data is expected in mid-2013.

"The Kinect 2 Study for NBI-98854 will round out our dose response database with over 200 subject exposures to NBI-98854 for up to three months of duration," said Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences. "This extensive dataset will serve as the basis for our end of Phase II meeting with the FDA planned for the second half of 2013."

Kinect 2 Study Design

The Kinect 2 Study is a randomized, parallel, double-blind, placebo-controlled, dose titration Phase IIb clinical trial utilizing the capsule formulation of NBI-98854 in moderate to severe tardive dyskinesia patients with an underlying mood disorder (e.g., bipolar disorder), schizophrenia or schizoaffective disorder, or a gastrointestinal disorder with exposure to metoclopramide. This 90 subject study will assess once-daily NBI-98854 over a six-week placebo-controlled dosing period. Half of the randomized subjects will receive placebo and half will receive NBI-98854. The NBI-98854 dosing regimen will begin with a once-daily dose of 25mg for the initial two weeks. At the completion of the initial two weeks of dosing, based on certain efficacy and safety criteria, patients may be titrated to a once-daily 50mg dose, or continue on the once-daily 25mg dose for the following two-week period. At the completion of the second two weeks of treatment another efficacy and safety assessment is performed and patients may again be titrated to a once-daily 75mg, 50mg or 25mg dose for the final two weeks of treatment. The primary endpoint of the study is a comparison of placebo vs. active scores utilizing the Abnormal Involuntary Movement Scale (AIMS) at the end of week six.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs